利用遗传代理研究终生心脏钠通道阻滞的影响
多队列观察研究纳入超百万人,分析SCN5A T220I变异对心律失常的影响。该变异模拟终生钠通道阻滞,降低房颤风险(HR 0.56)和心律失常死亡(HR 0.65),缩短QT间期,但增加病态窦房结综合征易感性,心肌梗死后增加死亡风险。
要点
- T220I变异与房颤风险降低相关(HR 0.56),并降低心律失常死亡风险(HR 0.65)。
- T220I缩短QT间期,但增加病态窦房结综合征易感性,尤其老年人群。
- 心肌梗死后T220I增加死亡风险,10-15年后恢复至基线水平。
核心结论
- SCN5A T220I变异作为心脏钠通道阻滞的遗传代理,揭示了对心律失常的保护作用及潜在临床启示。
主要发现
- T220I对房颤有保护作用(病因特异性HR 0.56,95%CI 0.50-0.63,P<0.0001)。
- T220I对心律失常死亡有保护作用(HR 0.65,95%CI 0.46-0.92,P=0.015),对总死亡率无显著影响(HR 0.92,P=0.27)。
- T220I缩短QT间期(-7.49 ms,95%CI -10.07至-4.91 ms,P=0.0037,n=3188),在英国生物银行重复(n=66 616)。
- T220I增加病态窦房结综合征易感性,主要见于老年组。
- T220I对(左)心力衰竭和扩张型心肌病有保护作用;心肌梗死后增加死亡风险,10-15年后恢复至基线。
临床怎么用
- T220I变异可降低高遗传负荷(高多基因评分)的房颤风险至人群平均水平。
- 研究提示心脏钠通道阻滞在心肌梗死后的应用需谨慎,因可能增加死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation and other cardiac arrhythmias pose a major public health burden, but prevention remains difficult. We investigated a genetic variant that we found to act like a natural lifelong cardiac sodium channel blockade. METHODS: We studied the impact of the Finnish-enriched SCN5A missense variant (rs45620037 [T220I]) on cardiac arrhythmias, associated mortality, and ECG phenotypes in a multicohort observational study with >1 million individuals across 3 cohorts (FinnGen, UK Biobank, and Health 2000). RESULTS: We identified protective effects of T220I on multiple common cardiac arrhythmias, most notably atrial fibrillation (cause-specific hazard ratio [HR], 0.56 [95% CI, 0.50-0.63]; P<0.0001), but also ventricular premature depolarization or ventricular tachycardia, as well as increasing susceptibility to conduction-slowing conditions, such as sick sinus syndrome (mostly in older age groups). Overall, T220I conveyed protection from death resulting from cardiac arrhythmia (HR, 0.65 [95% CI, 0.46-0.92]; P=0.015) without a significant effect on overall mortality risk (HR, 0.92; P=0.27). T220I heterozygosity had similar electrophysiological effects as some pharmacological sodium channel blockers, such as significantly shortening QT intervals (-7.49 ms [95% CI, -10.07 to -4.91] ms; P=0.0037; n=3188) in the Health 2000 cohort, which we replicated in the UK Biobank (n=66 616). In addition, T220I protected from (left) heart failure and dilated cardiomyopathy. After myocardial infarction, we found that T220I increased mortality risk, consistent with known sodium channel blocker effects, which, however, normalized to baseline 10 to 15 years after myocardial infarction. We found that T220I could lower a high genetic burden (ie, a high polygenic score) for atrial fibrillation to population average. CONCLUSIONS: The SCN5A T220I variant, consistent with a previously described weak loss-of-function effect, acted like a genetic proxy for cardiac sodium channel blockade. This enabled us to gain new potentially clinically relevant insights for pharmacological sodium channel blockade, such as after myocardial infarction, which would be too risky to investigate with clinical trials. Our findings may also inspire redesign of cardiac sodium channel blockers.
引用
- Wanner JS, Krafft M, Niiranen T, et al. Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. Circulation. 2025. PMID: 41277422. doi:10.1161/CIRCULATIONAHA.125.075057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。